April 21 Financial Quick Takes: ORIC’s IPO plans; plus venture rounds for Magpie, Cloudbreak, ReAlta, New Horizon, Zikani

ORIC sets terms for planned IPO

In an updated prospectus, oncology company ORIC Pharmaceuticals Inc. proposed to sell 5 million shares at $14-$16 in a planned IPO on NASDAQ. At the midpoint, a sale of that many shares would raise $75 million and value ORIC at $394.4 million. The company’s lead program, ORIC-101, is a GCCR antagonist that is in Phase Ib testing in combination with Xtandi enzalutamide to treat prostate cancer, as well as a separate Phase Ib trial in combination with Abraxane nab-paclitaxel in solid tumors (see “ORIC Raises $55M”)...